* Q4 results due on Thursday, 5 February * Estimates up 2-4% organically, but neutralised by FX * Ma...
* Negative FX and calendar effects * We trim '25e-'27e EBIT by 2% * Trading at 9x NTM EV/EBIT FX an...
NextCell yesterday announced six-year follow-up data for ProTrans in type 1 diabetes, confirming tha...
Redeye shares its view on Sleep Cycle ahead of the Q4 report, due on February 4.
Redeye shares its view on Physitrack ahead of the preliminary trading update scheduled for 29 Januar...
Following a prolonged period of valuation pressure, the biotech sector regained momentum through 202...
The public release of Xspray’s CRL on openFDA yesterday triggered a double-digit intraday decline in...
This Monday, Perpetua Medical invited investors, media, and the public to virtually attend a Live St...
* Q4e: 4% organic sales growth, 11% adj. EBITA margin * We cut estimates on the downgraded outlook *...
* Wins a SEK 280m contract, starting in Q1'26 * Pure software delivery, supporting a stronger margin...
* Targeting a huge unmet medical need * Revised best-in-class potential * Fair value range of SEK 0...
Gofore reported December sales in line with our estimate.
Alcadon announced this morning that it will discontinue its German operations, which comes as no maj...
Redeye comment on GiG’s Q4-trading update which showed softer performance than expected while the co...
Redeye provides updated estimates and a new fair value range for BONESUPPORT following the prelimina...
Redeye retains its positive view of Addnode in this Q4 Preview.
Duell's fiscal year 2026 got off to a challenging start, as sales declined 12% y/y.
Redeye comments on BONESUPPORT's announced preliminary Q4 2025 sales and sales growth target for 202...
We refresh our investment case for Cereno Scientific as the company enters a key value inflection pe...
Redeye gives an initial view of the readout with ELC-100 in NETs and slightly raise our valuation.
